C. Mazzoldi

C. Mazzoldi

Auto-generated profile, based on publicly available information

C. Mazzoldi

Department of Veterinary Medical Sciences, Alma Mater Studiorum - University of Bologna, Via Tolara di Sopra 50, 40064, Ozzano dell'Emilia, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2023 in Journal of Veterinary Cardiology
Verified
Journal Article
Open access
GRGiovanni Romito
Giovanni Romito
AEA. Elmi
A. Elmi
Carlo GuglielminiCarlo Guglielmini
Carlo Guglielmini
HPH. Poser
H. Poser
CVCarlotta Valente
Carlotta Valente
MCM. Cipone
M. Cipone
Transient myocardial thickening (TMT) in cats is a poorly characterized clinical entity. Therefore, this study aimed to provide descriptions of additional cats diagnosed with this clinical phenomenon. For this multicenter observational retrospective study, cats diagnosed with TMT were searched in three medical databases. TMT was defined for cats with at least two echocardiograms showing an increased end-diastolic left ventricular wall thickness (LVWTd; i.e. ≥6 mm) at presentation and subsequent echocardiographic normalization (i.e. LVWTd <5.5 mm). Signalment, history, clinical, laboratory, therapeutic, and outcome data were retrieved. 27 cats were included. The median age was 3 years. In 9/27 cats, an antecedent event was documented. At admission, 27/27 cats had evidence of myocardial injury (median value of cardiac troponin I 5.5 ng/mL), 25/27 cats had congestive heart failure, 13/27 cats had hypothermia, 8/27 cats had systemic hypotension, 7/27 cats had bradycardia, and 7/27 cats had electrocardiographic evidence of an arrhythmia. The median LVWTd was 6.4 mm. A potential cause of myocardial injury was identified in 14/27 cats. The median time from diagnosis to a significant reduction in LVWTd was 43 days. TMT can be diagnosed in a wide range of cats, including young subjects. An antecedent predisposing event and/or a possible causative trigger can be identified in some. The reduction in LVWTd that defines this phenomenon usually occurs over a variable time frame. This study represents the largest investigation of TMT in cats and provides additional information on this uncommon clinical entity.

19 March 2024 in Journal of Veterinary Cardiology
Verified
Journal Article
Open access
GRGiovanni Romito
Giovanni Romito
NGN. Gemma
N. Gemma
FDFrancesco Dondi
Francesco Dondi
CMC. Mazzoldi
C. Mazzoldi
SFSabrina Fasoli
Sabrina Fasoli
MCM. Cipone
M. Cipone
Studies on the use of amiodarone or sotalol are limited in dogs. Therefore, this study aimed to provide data on the efficacy and safety of these drugs in dogs with ventricular tachyarrhythmia (VT) and/or supraventricular tachyarrhythmia (SvT). Dogs with VT and/or SvT treated with amiodarone or sotalol as a first-line therapy were retrospectively evaluated. Signalment, clinical, diagnostic, therapeutic, and outcome data were retrieved. For VT, efficacy was demonstrated through a decrease of the Lown-Wolf grade to less than five or a reduction of at least 85% in the number of ventricular premature complexes observed on Holter monitoring. For SvT, efficacy was represented by cardioversion or a reduction in the mean heart rate on Holter monitoring ≤140 beats/min. Treatment-related side effects (TRSEs) were classified as clinically relevant and irrelevant. Statistical analysis was performed to compare data before and after antiarrhythmic prescription. Sixty-four dogs were included. Amiodarone and sotalol were efficacious in treating both VT (85.7% and 90.0% of cases, respectively) and SvT (75% and 71.4% of cases, respectively). No significant differences were found when comparing their efficacy rates in dogs with VT and SvT (P=0.531 and 0.483, respectively). Clinically relevant TRSEs were rare with both amiodarone and sotalol (8.3% and 5% of cases, respectively), while clinically irrelevant TRSEs occurred more frequently with amiodarone (29.2%) than with sotalol (10%). In dogs with tachyarrhythmias, amiodarone and sotalol are generally efficacious and safe, as clinically relevant TRSEs seem rare. This study provides novel data on the effects of amiodarone and sotalol in dogs with tachyarrhythmias.

7 November 2024 in Journal of Veterinary Cardiology
Verified
Journal Article
Open access
GRGiovanni Romito
Giovanni Romito
MBM. Bertarello
M. Bertarello
CMC. Mazzoldi
C. Mazzoldi
SFSabrina Fasoli
Sabrina Fasoli
FDF. Dondi
F. Dondi
Carlo GuglielminiCarlo Guglielmini
Carlo Guglielmini
Studies comparing the effects of antiarrhythmic protocols used for rate control in dogs with secondary atrial fibrillation (AF) are currently limited; therefore, this study aimed to report detailed data on the efficacy and therapy-related side-effects (TRSEs) of different antiarrhythmic protocols in dogs with secondary AF. Dogs with secondary AF treated with combination therapy with diltiazem and digoxin (CTDilt+Digox), diltiazem monotherapy (MTDilt), digoxin monotherapy (MTDigox), or amiodarone monotherapy (MTAmiod) were retrospectively evaluated. Signalment, clinical, diagnostic, therapeutic, and outcome data were retrieved. Electrocardiographically, antiarrhythmic efficacy was defined by a reduction in the mean heart rate on Holter monitoring ≤125 beats/minutes. Statistical analysis was performed to compare selected data, including the rate of efficacy and TRSEs as well as the median survival time, between dogs treated with different antiarrhythmic protocols. Fifty-four dogs were included, with 28 receiving the CTDilt+Digox and 26 receiving monotherapies (MTDigox = 16; MTDilt = 5; MTAmiod = 5). The efficacy rate documented in dogs treated with CTDilt+Digox was significantly higher than that observed in dogs from the composite monotherapy group (i.e., MTDilt+MTDigox+MTAmiod) (P=0.048). The rate of TRSEs documented in dogs treated with CTDilt+Digox was similar to that observed in dogs from the composed monotherapy group (P=0.129). The median survival time documented in dogs treated with CTDilt+Digox was significantly longer than that observed in dogs of the MTDigox group (P=0.01). In dogs with secondary AF we included, CTDilt+Digox was well tolerated and provided clinically relevant benefits compared to the use of a single antiarrhythmic drug. Retrospective design; heterogeneous sample size of categories analyzed; clinicopathological data available for many, but not all, dogs. Our findings support the indication to generally consider CTDilt+Digox as a first-line antiarrhythmic treatment in dogs with secondary AF.

24 May 2025 in Journal of Veterinary Cardiology
Verified
Journal Article
Open access
GRGiovanni Romito
Giovanni Romito
CMC. Mazzoldi
C. Mazzoldi
LCL. Calebotta
L. Calebotta
PCP. Castagna
P. Castagna
NPN.G. Pelle
N.G. Pelle
Carlo GuglielminiCarlo Guglielmini
Carlo Guglielmini
Information on the use of hydrochlorothiazide (HCTZ) in dogs with relapsing congestive heart failure (CHF) due to myxomatous mitral valve disease (MMVD) is limited. Therefore, the aim of this study was to provide data on HCTZ's short- and long-term effects in canine MMVD. Signalment, clinical, diagnostic, therapeutic, and outcome data of dogs with relapsing CHF due to MMVD treated with HCTZ were retrospectively reviewed. The initial time point was the day HCTZ was introduced for a CHF relapse. Optimized criteria were used to determine the appropriate timings for evaluating HCTZ's short-term effects on laboratory and echocardiographic variables and its long-term impact on CHF management. Thirty-eight dogs were included. The initial median dose of HCTZ was 0.8 mg/kg/die. At a median of seven days after HCTZ prescription, creatinine, urea, and total calcium levels significantly increased, while sodium and potassium levels significantly decreased (P: from 0.045 to <0.0001). While no dog developed severe electrolyte abnormalities, some dogs showed severe increases in creatinine and urea. After a median of 95 days, no significant echocardiographic changes developed (P: from 0.74 to 0.13). Episodes of CHF were more frequent before (median: one every 68 days) than after (median: one every 124 days) HCTZ prescription (P=0.006). The study limitations included the retrospective design of the study; not all dogs were included both in the short- and long-term analysis. In canine MMVD, HCTZ is useful in long-term management of relapsing CHF. However, in the short term, HCTZ can cause laboratory abnormalities, primarily increased creatinine and urea.

6 April 2025 in Journal of Veterinary Cardiology
Verified
Journal Article
Open access
GRGiovanni Romito
Giovanni Romito
CMC. Mazzoldi
C. Mazzoldi
MBM. Di Benedetto
M. Di Benedetto
SSSilvia Sabattini
Silvia Sabattini
An 11-year-old Cavalier King Charles spaniel with a previous diagnosis of preclinical myxomatous mitral valve disease (MMVD) was presented with respiratory distress and abdominal distension. Lung edema and ascites were diagnosed. Echocardiography revealed a progression of the MMVD as it was associated with a moderate enlargement of the left-sided cardiac chambers and an atrial septal defect (ASD). The latter was hypothesized to be primarily due to a rupture of the interatrial septum caused by MMVD. Moreover, a hyperechoic irregular mass was documented inside the left atrium. At that time, the primary differential diagnosis included intracardiac thrombosis (ICT) and mural endocarditis. Comprehensive diagnostic tests subsequently ruled out extracardiac prothrombotic triggers; moreover, both blood and urine cultures tested negative. Despite the administration of cardiac and supportive therapies (including antithrombotic drugs), the dog died 138 days after presentation. Necropsy confirmed the presence of MMVD (type IV lesions according to Pomerance and Whitney's classification system) associated with remodeling of the left-sided cardiac chambers, multiple left atrial (LA) jet lesions, and ASD. Endocarditis was ruled out, and the LA mass was demonstrated to be an ICT entrapped in the ASD. In light of premortem and postmortem findings, the turbulent blood flow secondary to the mitral valve insufficiency and ASD, along with the extensive LA endothelial damage, were considered likely triggering factors for the development of ICT. This case suggests that, although ICT represents an extremely rare complication of cardiac diseases in dogs, it can potentially develop when canine MMVD is particularly advanced.

30 April 2026 in Journal of Veterinary Cardiology
Verified
Journal Article
Closed access
SOS. Oricco
S. Oricco
SCSerena Crosara
Serena Crosara
CMC. Mazzoldi
C. Mazzoldi
IAI. Apolloni
I. Apolloni
CGC. Guiducci
C. Guiducci
GRG. Romito
G. Romito